How earlier signals of misconnection may help pharma identify trust breakdowns before they show up as lagging measures in adherence, initiation, engagement, and outcomes.
Feature|Articles|September 15, 2026
Pharma Now Has Two Audiences — People and Machines: Q&A with Stewart Gandolf
Author(s)Mike Hollan, Stewart Gandolf
Pharma brands with all the right information are still invisible to AI — and why silence is the bigger risk than inaccuracy.
Advertisement
Advertisement
AI became the most common way people search the internet. Not surprisingly, the new technology impacted that way that people search, including patients. Now, instead of keyword searching, many experts are saying that people search by question.
Related to this article
FDA Approves Expanded Indication for Camzyos for Symptomatic Obstructive Hypertrophic Cardiomyopathy
FDA has expanded Camzyos's approval to treat symptomatic obstructive hypertrophic cardiomyopathy in pediatric patients as young as 12.
MRD Testing Is Becoming the Most Important Tool in Oncology Drug Development: Q&A with Eric Matthews
MRD testing is transforming oncology trials — compressing timelines, enriching populations, and generating earlier answers.
Life sciences spends billions on compliance — but WhatsApp, iMessage, and SMS conversations between field teams and HCPs remain invisible to oversight.
New U.S. guidance exempts orphan drugs, nuclear medicines, cell and gene therapies, and other specialty products from the 100% pharmaceutical tariff when imported from 19 named countries.
While the FDA weighs a narrow, regulated path for compounded peptides, its enforcement arm is already taking action.
FDA this week cleared three new treatments: Lilly's Olumiant for adolescent alopecia areata, AbbVie's Juvmo for Parkinson's disease, and Mirum and Incyte's Atebrioz for the rare bone disorder FOP.
Compounding pharmacies that set their own safety and accreditation standards now stand the best chance of keeping patient access intact before heavier regulation does it for them.
Advertisement
Advertisement